This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Morphic Holding Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Morphic Holding's earnings have been declining at an average annual rate of -30.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 3% per year.
Belangrijke informatie
-30.3%
Groei van de winst
18.8%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | -3.0% |
Rendement op eigen vermogen | -29.1% |
Nettomarge | n/a |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
Jun 26We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely
Jan 20Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth
Sep 29We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow
Jun 07What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates
Feb 15We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely
Jan 03What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates
Nov 08Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M
Aug 03Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)
May 06Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)
Mar 01Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
Feb 17We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn
Nov 03Morphic: Pioneering Integrin Medicines
Oct 13Opbrengsten en kosten
Hoe Morphic Holding geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 0 | -180 | 47 | 0 |
31 Mar 24 | 0 | -161 | 41 | 0 |
31 Dec 23 | 1 | -152 | 39 | 0 |
30 Sep 23 | 7 | -136 | 37 | 0 |
30 Jun 23 | 9 | -130 | 35 | 0 |
31 Mar 23 | 69 | -64 | 34 | 0 |
31 Dec 22 | 71 | -59 | 32 | 0 |
30 Sep 22 | 74 | -56 | 32 | 0 |
30 Jun 22 | 75 | -51 | 31 | 0 |
31 Mar 22 | 19 | -106 | 29 | 0 |
31 Dec 21 | 20 | -96 | 28 | 0 |
30 Sep 21 | 16 | -92 | 25 | 0 |
30 Jun 21 | 39 | -61 | 23 | 0 |
31 Mar 21 | 43 | -50 | 20 | 0 |
31 Dec 20 | 45 | -45 | 18 | 0 |
30 Sep 20 | 39 | -47 | 17 | 0 |
30 Jun 20 | 19 | -61 | 15 | 0 |
31 Mar 20 | 17 | -55 | 13 | 0 |
31 Dec 19 | 17 | -43 | 10 | 0 |
30 Sep 19 | 21 | -29 | 9 | 0 |
30 Jun 19 | 15 | -27 | 7 | 0 |
31 Mar 19 | 9 | -24 | 6 | 0 |
31 Dec 18 | 3 | -24 | 5 | 0 |
Kwaliteitswinsten: MORF is currently unprofitable.
Groeiende winstmarge: MORF is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: MORF is unprofitable, and losses have increased over the past 5 years at a rate of 30.3% per year.
Versnelling van de groei: Unable to compare MORF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: MORF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Rendement op eigen vermogen
Hoge ROE: MORF has a negative Return on Equity (-29.08%), as it is currently unprofitable.